Europe
Biopharma companies strengthen the C-suite and board of directors with these appointments.
Shares of Mallinckrodt are down more than 45% in premarket trading after multiple reports indicate the company plans a restructuring in the wake of the opioid crisis that has promoted a number of lawsuits that implicate the company for its sales practices in the United States.
The companies will develop a group of immunotherapies that inhibit the cGAS/STING pathway to treat a broad range of inflammatory and autoimmune diseases.
Biofidelity Ltd announces it has secured £0.75 million seed financing, following its formation earlier this year.
Discngine announces that Lundbeck has selected its proprietary 3decision® collaborative platform to manage the pharma company’s structural knowledge related to protein and ligand 3D structures.
Atriva Therapeutics GmbH announced its participation in four upcoming partnering conferences worldwide.
Polyphor AG focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics, publishes today its financial results for the first half of 2019 and announces a realignment of the strategy.
Apogenix announced that a new publication in Cancer Management and Research[1] reviews asunercept as a promising treatment option for patients with other malignancies beyond glioblastoma and myelodysplastic syndromes.
Robocath announces that it has raised €5 million to support the rollout of its robotic platform in strategic European target markets.
Forbion announces that it has participated in a £100 million Series B financing of Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies.
PRESS RELEASES